



Reply: pleuropulmonary blastoma-like peritoneal sarcoma and *DICER1*-associated sarcomas: toward a unified nomenclature

Louis P. Dehner¹ · D. Ashley Hill² · Douglas R. Stewart³ · Kris Ann P. Schultz^{4,5}

Received: 7 March 2021 / Revised: 16 March 2021 / Accepted: 16 March 2021 / Published online: 19 April 2021
© The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2021

To the Editor:

We appreciate the thoughtful commentary by Drs. McCluggage and Foulkes in response to our manuscript “Pleuropulmonary blastoma-like peritoneal sarcoma” focusing on a new manifestation of *DICER1* pathogenic variation.

DICER1-related cancers are hardly the first set of molecularly linked cancers seen within the context of tumor predisposition. The spectrum of cancers seen in the context of Li-Fraumeni syndrome, familial retinoblastoma and familial adenomatous polyposis are just three of countless of other examples [1]. A previously undefined neoplasm of the lung in children younger than 10 years of age with a unique age-associated progression from a circumscribed multilocular cyst, initially thought to be a type of congenital pulmonary airway malformation, to a high grade, multi-patterned sarcoma, became the entity known today as pleuropulmonary blastoma (PPB) [2, 3]. The cystic variant of PPB had been reported in the literature prior to the report of the highly malignant solid PPB as embryonal rhabdomyosarcoma (eRMS) arising in congenital lung cysts [4, 5]. From this evolution of a “cystic

eRMS”, the collage of undifferentiated blastema accompanied by neoplastic cartilage, spindle cell sarcoma, RMS and anaplastic cells emerged as the morphologic template of PPB.

As McCluggage and Foulkes point out in their correspondence and as recognized through a series of studies through the International Pleuropulmonary Blastoma/*DICER1* Registry and others beginning in the 1990s, there is more to the story than simply PPB [6]. However, the clinical phenotype of *DICER1* pathogenic variation is not simply confined to a group of sarcomas arising in a number of extrapulmonary sites, but also non-sarcomas such as pituitary blastoma, pineoblastoma, ciliary body medulloepithelioma (CBME), chondromesenchymal hamartoma, multinodular goiter harboring papillary thyroid carcinoma, pediatric poorly differentiated thyroid carcinoma, multicystic hepatic lesions and cystic nephroma (CN). It is within the setting of CBME, CN and moderately/poorly differentiated Sertoli-Leydig cell tumor (SLCT) that the sarcomatous motif of the archetypical PPB first manifested itself.

In the ideal world, one could hope for a consensus in terminology for these *DICER1*-related neoplasms. Indeed, our group is very interested in issues of nomenclature within *DICER1* with considerations including impact on clinical care and research, equity, accessibility and importantly, patient perspective. Consideration of impact on clinical care must include issues of availability and timing of molecular testing. Consideration of patient perspectives ensures that terms such as “mutant” are not part of the new diagnosis experience of children, adolescents, adults and their family members.

Regardless of the name, however, in most cases these tumors will be recognized by their histologic features ranging from a primitive small cell neoplasm or high grade sarcoma of the CNS in a child to a SLCT of the ovary [7, 8]. The sarcoma in the CNS may only demonstrate a single pattern in a biopsy or several in a tumor

✉ Kris Ann P. Schultz
krisann.schultz@childrensmn.org

¹ Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA

² Department of Pathology, Center for Cancer and Immunology Research, Children’s National Medical Center, Washington, D.C., USA

³ Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA

⁴ International Pleuropulmonary Blastoma/*DICER1* Registry, Children’s Minnesota, Minneapolis, MN, USA

⁵ Cancer and Blood Disorders Program, Children’s Minnesota, 2530 Chicago Avenue South CSC-175, Minneapolis, MN, USA

whose features are indistinguishable from metastatic PPB to the brain. The SLCT with cystic ERMS and nodules of cartilage is a *DICER1*-related neoplasm but it remains a heterologous SLCT.

The suspicion or recognition of these tumors is based on the histopathologic features and as such, the pathologist must be aware of the morphologic spectrum of *DICER1*-related tumors. If the pathologist does not appreciate the potential implications of a CN, peritoneal sarcoma or RMS of the uterus, focus on terminology and classification is beside the point. An index of suspicion with an awareness of the existence of the various *DICER1*-related tumors should be set in motion for those neoplasms with cysts in the lung, kidney, liver and peritoneum whose histologic features include RMS, nodules of cartilage and anaplasia. A delicate layer of rhabdomyoblasts in the septum beneath the peritoneum or the ciliated epithelium of the fallopian tube or a polyp of cervix should serve as an important prompt to the pathologist to suggest to the clinician that the tumor may be *DICER1*-related and the patient may have a germline *DICER1* variant [9–12]. After that important juncture in patient care, then we can then proceed with classification—PPB-like sarcoma or *DICER1* sarcoma. We would argue that the pathologist who is familiar with the cystic and solid patterns of PPB has a visual framework from which to suggest that the “PPB-like” sarcoma should be followed up by tumor molecular testing and appropriate genetic counseling and testing [13].

We appreciate the thoughtful response to our study and our continued shared interest in *DICER1*-related research.

Compliance with ethical standards

Conflict of interest The authors have no conflicts of interest to disclose. Dr. Hill is owner of ResourcePath LLC, a company which does research and development of laboratory tests including for *DICER1* cancers. That work is unrelated to the information presented in this article.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Capasso M, Montella A, Tirelli M, Maiorino T, Cantalupo Stolascon A. Genetic Predisposition to Solid Pediatric Cancers. *Front Oncol.* 2020;10:590033.
2. Manivel JC, Priest JR, Watterson J, Steiner M, Woods WG, Wick MR, et al. Pleuropulmonary blastoma. The so-called pulmonary blastoma of childhood. *Cancer.* 1988;62:1516–26.
3. Priest JR, McDermott MB, Bhatia S, Watterson J, Manivel JC, Dehner LP. Pleuropulmonary blastoma: a clinicopathologic study of 50 cases. *Cancer.* 1997;80:147–61.
4. Ueda K, Gruppo R, Unger F, Martin L, Bove K. Rhabdomyosarcoma of lung arising in congenital cystic adenomatoid malformation. *Cancer.* 1977;40:383–8.
5. Krous HF, Sexauer CL. Embryonal rhabdomyosarcoma arising within a congenital bronchogenic cyst in a child. *J Pediatr Surg.* 1981;16:506–8.
6. Dehner LP, Messinger YH, Schultz KA, Williams GM, Wikenheiser-Brokamp K, Hill DA. Pleuropulmonary Blastoma: evolution of an Entity as an Entry into a Familial Tumor Predisposition Syndrome. *Pediatr Dev Pathol.* 2015;18:504–11.
7. Schultz KAP, Harris AK, Finch M, Dehner LP, Brown JB, Gershenson DM, et al. *DICER1*-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. *Gynecol Oncol.* 2017;147:521–7.
8. de Kock L, Priest JR, Foulkes WD, Alexandrescu S. An update on the central nervous system manifestations of *DICER1* syndrome. *Acta Neuropathol.* 2020;139:689–701.
9. Dehner LP, Jarzembowski JA, Hill DA. Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. *Mod Pathol.* 2012;25:602–14.
10. McCluggage WG, Apellaniz-Ruiz M, Chong AL, Hanley KZ, Velazquez Vega JE, McVeigh TP, et al. Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic *DICER1* Mutations. *Am J Surg Pathol.* 2020;44:738–47.
11. Schultz KAP, Nelson A, Harris AK, Finch M, Field A, Jarzembowski JA, et al. Pleuropulmonary blastoma-like peritoneal sarcoma: a newly described malignancy associated with biallelic *DICER1* pathogenic variation. *Mod Pathol.* 2020;33:1922–9.
12. de Kock L, Yoon JY, Apellaniz-Ruiz M, Pelletier D, McCluggage WG, Stewart CJR, et al. Significantly greater prevalence of *DICER1* alterations in uterine embryonal rhabdomyosarcoma compared to adenocarcinoma. *Mod Pathol.* 2020;33:1207–19.
13. Schultz KAP, Williams GM, Kamihara J, Stewart DR, Harris AK, Bauer AJ, et al. *DICER1* and Associated Conditions: identification of At-risk Individuals and Recommended Surveillance Strategies. *Clin Cancer Res.* 2018;24:2251–61.